{
      "Rank": 249,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants with moderate to severe acute respiratory distress syndrome (6 patients)",
            "Participants with moderate to severe acute respiratory distress syndrome (10 patients)",
            "Participants with moderate to severe acute respiratory distress syndrome (10 patients)"
      ],
      "ArmGroupInterventionName": [
            "Drug: HCR040 (Phase 1)",
            "Drug: Placebo (Phase 2)",
            "Drug: HCR040 (Phase 2)"
      ],
      "ArmGroupLabel": [
            "HCR040 (Phase 1)",
            "Control group (Phase 2)",
            "HCR040 (Phase 2)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT04289194"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The main objective of the study is to assess the feasibility, safety, and tolerability of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome."
      ],
      "BriefTitle": [
            "Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome"
      ],
      "CentralContactEMail": [
            "bcastro@histocell.com"
      ],
      "CentralContactName": [
            "Bego\u00f1a Castro, PhD"
      ],
      "CentralContactPhone": [
            "+34 94 656 7900"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "April 16, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000008171",
            "D000012140",
            "D000012120",
            "D000007235",
            "D000007232",
            "D000055370"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Lung Injury"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC08",
            "BC16",
            "BC26",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "Wounds and Injuries",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M15507",
            "M14117",
            "M9445",
            "M14116",
            "M27297",
            "M27296",
            "M10320",
            "M14129",
            "M14109",
            "M25022",
            "M9431",
            "M9428",
            "T4927",
            "T192",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Inflammation",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Lung Injury",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Premature Birth",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Respiratory Distress Syndrome, Infant",
            "Acute Respiratory Distress Syndrome",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000012128",
            "D000012127",
            "D000055371",
            "D000013577"
      ],
      "ConditionMeshTerm": [
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Syndrome"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "HCR040 is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2.\n\nThe main purpose of this study is to evaluate the safety and tolerability of a single administration of HCR040 using: a) two sequential escalating doses administered 96 hours post-injury to participants with moderate to severe acute respiratory distress syndrome (ARDS); and b) the determined maximum tolerated dose administered 96 hours post-injury to participants with moderate to severe ARDS. The study also includes initial exploration of efficacy.\n\nTreatment is administered by intravenous injection.\n\nThe study has been divided into two phases:\n\nPhase 1 (open label): 6 participants with moderate to severe ARDS will be included in 2 sequential cohorts.\n\nPhase 2 (randomized, controlled, double-blind): 20 participants with moderate to severe ARDS will be randomly divided into two groups (control and treated)."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMen and women \u2265 18 years\nPatients with criteria of moderate to severe ARDS according to the Berlin Conference.\nBerlin criteria of moderate to severe ARDS given simultaneously during the 24 hours prior to entry into the study\nPatients with invasive mechanical ventilation in controlled mode (VC, PC or VCRP) adjusted to Vt\u22648 mL/kg, Ppl <30 cmH2O and minimum PEEP of 8 cmH2O\n\nExclusion Criteria:\n\nParticipation in a previous clinical study within 28 days prior to the ARDS situation\nAdministration of a previous cell therapy product in the 5 years prior to this ARDS clinical situation\nInability to obtain Informed Consent\nHemodynamic instability that contraindicates the intravenous cellular administration, within the defined time frame for inclusion in the study\nAlveolar hemorrhage or hemoptysis\nLTSV situation (Limitation of life support treatments)\nMajor trauma in the previous 5 days\nNeoplastic processes at any time\nEPOC or severe home asthma or any other type of chronic respiratory disease requiring respiratory oxygen\nKnown Child-Pugh liver disease score > B9\nPregnant women or women of childbearing age who are not using an adequate method of contraception, or who, if they are using it, are not willing to continue using it for the duration of the trial. If the patient is menopausal or sterile, it must be documented in the medical record\nWomen who are breastfeeding if unwillingly to stop at the time of recruitment\nPulmonary transplant\nKnown grade III or IV pulmonary hypertension\nStates of hypercoagulability\nHistory of DVP or PE in the last 6 months"
      ],
      "EnrollmentCount": [
            "26"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000891",
            "D000000890"
      ],
      "InterventionAncestorTerm": [
            "Anti-Infective Agents, Local",
            "Anti-Infective Agents"
      ],
      "InterventionArmGroupLabel": [
            "HCR040 (Phase 1)",
            "Control group (Phase 2)",
            "HCR040 (Phase 2)"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "All",
            "PhSol"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "All Drugs and Chemicals",
            "Pharmaceutical Solutions"
      ],
      "InterventionBrowseLeafAsFound": [
            "BeneFIX"
      ],
      "InterventionBrowseLeafId": [
            "M9070",
            "M21013",
            "M3366",
            "M3367"
      ],
      "InterventionBrowseLeafName": [
            "Hydrogen Peroxide",
            "Pharmaceutical Solutions",
            "Anti-Infective Agents",
            "Anti-Infective Agents, Local"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "(Phase 1) Intravenous administration. Open label dose escalation, 3 patients in cohort 1 (1 million cells/kg) and 3 patients in cohort 2 (2 million cells/kg)",
            "(Phase 2) Intravenous administration of vehicle solution",
            "(Phase 2) Intravenous administration of the maximum tolerated dose (1 million cells/kg or 2 million cells/kg)"
      ],
      "InterventionMeshId": [
            "D000006861"
      ],
      "InterventionMeshTerm": [
            "Hydrogen Peroxide"
      ],
      "InterventionName": [
            "HCR040 (Phase 1)",
            "Placebo (Phase 2)",
            "HCR040 (Phase 2)"
      ],
      "InterventionOtherName": [
            "Allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2",
            "Saline solution",
            "Allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2"
      ],
      "InterventionType": [
            "Drug",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Acute Respiratory Distress Syndrome",
            "mesenchymal stem cells",
            "anti-inflammation",
            "allogenic",
            "ARDS",
            "acute lung injury",
            "cell therapy"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "May 14, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "May 13, 2021"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Histocell, S.L."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Barakaldo",
            "Madrid"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [
            "Fermin Labayen Beraza, MD",
            "Fermin Labayen Beraza, MD",
            "Pablo Serna, MD",
            "Victoria Boado, MD",
            "Tom\u00e1s Mu\u00f1oz, MD"
      ],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Principal Investigator",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator"
      ],
      "LocationCountry": [
            "Spain",
            "Spain"
      ],
      "LocationFacility": [
            "Hospital Universitario de Cruces",
            "Fundaci\u00f3n Jim\u00e9nez D\u00edaz"
      ],
      "LocationState": [
            "Bizkaia"
      ],
      "LocationStatus": [
            "Recruiting",
            "Completed"
      ],
      "LocationZip": [
            "48903",
            "28040"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase 1/2 Clinical Study to Assess the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of HCR040, Allogeneic Adipose-derived Adult Mesenchymal Stem Cells, in Acute Respiratory Distress Syndrome"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Histocell, S.L."
      ],
      "OrgStudyId": [
            "ALICELL-CT-01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital de Cruces"
      ],
      "OverallOfficialName": [
            "Fermin Labayen Beraza, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "August 15, 2021"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Number of adverse events as a measure of safety and tolerability of a single dose of HCR040 when administered by intravenous injection"
      ],
      "PrimaryOutcomeTimeFrame": [
            "One year"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "2019-002688-89"
      ],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "EudraCT Number"
      ],
      "SecondaryOutcomeDescription": [
            "SOFA index from 0 to 4 where lower scores represent improvement",
            "Murray scale from 0 to 4 where lower scores represent improvement"
      ],
      "SecondaryOutcomeMeasure": [
            "Average stay in the Intensive Care Unit (ICU) 28 days after the administration of HCR040",
            "Sequential Organ Failure Assessment (SOFA) index at 3, 7, 14, 21, and 28 days after the administration of HCR040",
            "Mechanical ventilation-free days 28 days after the administration of HCR040",
            "Percent mortality 28 days after the administration of HCR040",
            "Daily pulmonary mechanics values (Ppl, DP, CRS)",
            "Determination of lung damage using the Murray scale at day 3, 7, 14 and 28 after the administration of HCR040",
            "Vasopressor-free days 28 days after the administration of HCR040",
            "ICU-free days 28 days after the administration of HCR040"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Day 28",
            "Day 28",
            "Day 28",
            "Day 28",
            "One year",
            "Day 28",
            "Day 28",
            "Day 28"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "December 10, 2019"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "April 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "February 28, 2020"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "February 26, 2020"
      ],
      "StudyFirstSubmitQCDate": [
            "February 26, 2020"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}